Sort   by:  
 Page size 
UnknownAlterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Purpose Alterations in DNA damage response and repair (DDR) genes are associated with increased mutation load and improved clinical outcomes in platinum-treated metastatic urothelial carcinoma. We examined the relationship between DDR alterations and response to PD-1/PD-L1 blockade. Methods Detailed...
S-EPMC6366295 | biostudies-literature
UnknownDouble-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.

Purpose

Vandetanib is an oral once-daily tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 and epidermal growth factor receptor. Vandetanib in combination with docetaxel was assessed in patients with advanced urothelial cancer (UC) who progressed o...
S-EPMC4104290 | biostudies-literature
UnknownPhase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Purpose

Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors. Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patien...
S-EPMC3532390 | biostudies-literature
UnknownSerum urate and cardiovascular events in the DCCT/EDIC study.
In type 2 diabetes, hyperuricemia is associated with cardiovascular disease (CVD) and the metabolic syndrome (MetS), but associations in type 1 diabetes (T1D) have not been well-defined. This study examined the relationships between serum urate (SU) concentrations, clinical and biochemical factors, ...
S-EPMC8271014 | biostudies-literature
GenomicsData access committee handling data access requests for biomarker data from the clinical trial IMvigor210.
Data Access Committee EGAC00001000945
EGAC00001000945 | EGA
GenomicsTGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
We examined tumours from a large cohort of patients with metastatic urothelial bladder cancer (mUC) treated with an anti–PD-L1 agent (atezolizumab) and identified major determinants of clinical response and immune escape. Whole transcriptome profiles were generated for 368 patients using TruSeq RNA ...
EGAS00001002556 | EGA
Genomicsena-DATASET-GNE-27-07-2018-23:28:18:139-1120 - samples
Tumor DNA was extracted from formalin-fixed and paraffin embedded tumors of a large cohort of bladder cancer patients before treatment with anti-PD-L1. Normal DNA was extracted from matched PBMCs. Whole exome sequencing was performed. This is a subset of patients for which RNA sequencing is also pro...
EGAD00001004218 | EGA
Genomicsena-DATASET-GNE-22-02-2018-22:43:32:906-1098 - samples
RNA was extracted from formalin-fixed and paraffin embedded tumors of a large cohort of bladder cancer patients before treatment with anti-PD-L1. RNA was sequenced using a capture based approach (exome capture, RNA access).
EGAD00001003977 | EGA
UnknownRetrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.
The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) curated consensus somatic mutation calls using whole exome sequencing (WES) and whole genome sequencing (WGS), respectively. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which ...
S-EPMC7505971 | biostudies-literature
Sort   by:  
 Page size